Literature DB >> 22940370

Retinal arteriolar responses to acute severe elevation in systemic blood pressure in cats: role of endothelium-derived factors.

Seigo Nakabayashi1, Taiji Nagaoka, Tomofumi Tani, Kenji Sogawa, Travis W Hein, Lih Kuo, Akitoshi Yoshida.   

Abstract

The purpose of this study was to investigate the roles of endothelium-derived factors in the retinal arteriolar responses to acute severe elevation in systemic blood pressure (BP) in cats. Acute elevation of mean arterial BP by 60% for 5 min was achieved by inflating a balloon-tipped catheter in the descending aorta. The retinal arteriolar diameter, flow velocity, wall shear rate (WSR) and blood flow (RBF) changes during BP elevation were assessed with laser Doppler velocimetry 2 h after intravitreal injections of nitric oxide (NO) synthase inhibitor l-NAME, cyclooxygenase inhibitor indomethacin, endothelin-1 receptor antagonists (BQ-123 for type A and BQ-788 for type B), or Rho kinase inhibitor fasudil. BP elevation caused a marked increase in retinal arteriolar flow velocity and WSR with slight vasoconstriction, resulting in an increase in RBF. The increases in velocity, WSR and RBF, but not diameter, were correlated with the increase in ocular perfusion pressure. With l-NAME or indomethacin, the increase in RBF upon BP elevation was significantly attenuated due to enhanced retinal arteriolar vasoconstriction. In contrast, BQ-123 and fasudil potentiated the increased RBF. BQ-788 had no effect on arteriolar diameter and hemodynamics. Our data suggest that acute elevation of BP by 60% leads to an increase in RBF due to the release of NO and prostanoids probably through a shear stress-induced vasodilation mechanism. The release of endothelin-1 and Rho kinase activation help to limit RBF augmentation by counteracting the vasodilation. It appears that the retinal endothelium, by releasing vasoactive substances, contributes to RBF regulation during acute severe elevation of systemic blood pressure.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22940370     DOI: 10.1016/j.exer.2012.08.007

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  6 in total

1.  VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.

Authors:  Travis W Hein; Robert H Rosa; Yi Ren; Wenjuan Xu; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

2.  Activation of the endothelin system mediates pathological angiogenesis during ischemic retinopathy.

Authors:  Chintan Patel; S Priya Narayanan; Wenbo Zhang; Zhimin Xu; Sangeetha Sukumari-Ramesh; Krishnan M Dhandapani; R William Caldwell; Ruth B Caldwell
Journal:  Am J Pathol       Date:  2014-09-06       Impact factor: 4.307

3.  Temporal development of retinal arteriolar endothelial dysfunction in porcine type 1 diabetes.

Authors:  Travis W Hein; Luke B Potts; Wenjuan Xu; Josh Z Yuen; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-03       Impact factor: 4.799

4.  Longitudinal stability of retinal blood flow regulation in response to flicker stimulation and systemic hyperoxia in mice assessed with laser speckle flowgraphy.

Authors:  Junya Hanaguri; Harumasa Yokota; Masahisa Watanabe; Lih Kuo; Satoru Yamagami; Taiji Nagaoka
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.379

5.  Longitudinal Changes in Retinal Blood Flow in a Feline Retinal Vein Occlusion Model as Measured by Doppler Optical Coherence Tomography and Optical Coherence Tomography Angiography.

Authors:  Takanari Wada; Youngseok Song; Tsuneaki Oomae; Kenji Sogawa; Takafumi Yoshioka; Seigo Nakabayashi; Kengo Takahashi; Tomofumi Tani; Akihiro Ishibazawa; Satoshi Ishiko; Akitoshi Yoshida
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

6.  Altered Retinal Hemodynamics and Mean Circulation Time in Spontaneously Hypertensive Rats.

Authors:  Wendy Leskova; Ravdeep Warar; Norman R Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.